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Results of studies conducted 10–20 years ago show the prominence of commercial information sources in the adoption
process of new drugs. Over the past decade, there has been a growing emphasis on practicing evidence-based medicine in
drug prescribing. This raises the question whether professional information sources currently counterbalance the inﬂuence
of commercial information sources in the adoption process. The aim of this study was to identify determinants inﬂuencing
the adoption of a new drug class, the angiotensin II receptor blockers (ARBs), by general practitioners (GPs) in The
Netherlands. A retrospective study was conducted to assess prevalent ARB prescribing for hypertensive patients using the
Integrated Primary Care Information (IPCI) database. We conducted a survey among all GPs who participated in the IPCI
project in 2003 to assess their exposure to commercial and professional information sources, perceived beneﬁts and risks of
ARBs, perceived inﬂuences of the professional network, and general characteristics. Multilevel logistic regression was
applied to identify determinants of ARB adoption while adjusting for patient characteristics. Data were obtained from 70
GPs and 9470 treated hypertensive patients. A total of 1093 patients received ARBs (12%). GPs who reported frequent use
of commercial information sources were more likely to prescribe ARBs routinely in preference to other antihypertensives,
whereas GPs who used a prescribing decision support system and those who were involved in pharmacotherapy education
were less likely to prescribe ARBs. Other factors that were associated with higher levels of ARB adoption included a more
positive perception of ARBs regarding their effectiveness in lowering blood pressure, and working in single-handed
practices or in rural areas. Aside from determinants related to the patient population, adoption of a new drug class among
Dutch GPs is still determined more by their reliance on promotional information than by their use of professional
information sources.
r 2006 Elsevier Ltd. All rights reserved.
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There is a lively debate about which medication
to choose in hypertensive treatment, fuelled by
controversy about possible limitations of large.
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ﬁndings as well as by ﬁnancial interests and
concerns (Frohlich, 2003; Moser, 2003). Quality
improvement programmes stress the relevance of
implementing clinical guidelines and practicing
evidence-based medicine, governments aim for cost
containments, and pharmaceutical industries aim to
make more proﬁts (Lexchin, 2002). Amidst these
forces, physicians have to decide about the place of
new antihypertensive drugs. Results of studies that
were conducted more than 20 years ago showed the
prominence of commercial information sources in
the adoption process of new drugs and the minor
inﬂuence of professional information sources
(Avorn, Chen, & Hartley, 1982; Peay & Peay,
1984). The inﬂuence of commercial information is
still a matter of concern, but there are few recent
empirical studies on the impact of various informa-
tion sources on drug choice and prescribing
behaviour (Caamano, Figueiras, & Gestal-Otero,
2002; Wazana, 2000). In an environment with a
growing emphasis on evidence-based medicine,
professional information sources might counter-
balance the inﬂuence of commercial information
sources in the adoption process.
Angiotensin II receptor blockers (ARBs) were
introduced in the market in 1995 as a new drug class
for hypertension after proving efﬁcacy in lowering
blood pressure. Evidence on hard endpoints such as
cardiovascular morbidity and mortality in patients
with hypertension was not available until 2002
(Dahlof et al., 2002). Due to this lack of evidence on
hard endpoints, the high costs, and the availability
of alternatives with proven effectiveness, ARBs
have not been recommended as ﬁrst-line treatment
for essential hypertension in most treatment guide-
lines (Grobbee, Tuut, & Hoes, 2001; JNC, 1997).
Nevertheless, the use of ARBs has increased
remarkably in the last 10 years (Garcia del Pozo,
Ramos Sevillano, de Abajo, & Mateos Campos,
2004; Greving et al., 2004).
Adoption rates of new drugs vary among
physicians and by type of drug (Dybdahl, Andersen,
Sondergaard, Kragstrup, & Kristiansen, 2004; In-
man & Pearce, 1993; McGavock, Webb, Johnston,
& Milligan, 1993; Steffensen, Sorensen, & Olesen,
1999; Tamblyn, McLeod, Hanley, Girard, & Hur-
ley, 2003). The adoption of new treatments in
clinical practice is the result of many factors. Based
on Rogers’ theoretical model for the diffusion of
innovations, the following factors can be identiﬁed:
(1) information sources used, (2) perceived char-acteristics of the new drug, (3) professional network
and norms, (4) general physician characteristics
(Rogers, 1995). In addition to this general frame-
work, decision-making theories can help us under-
stand how treatment choices are made on an
individual level (Sox, Blatt, Higgins, & Marton,
1988). Differences in drug choice can be related to
different perceived characteristics or expectations
about drugs, but also to differences in the relative
importance or value assigned to the various drug
aspects (Denig, Haaijer-Ruskamp, & Zijsling, 1988;
Denig, Witteman, & Schouten, 2002; Segal &
Hepler, 1985).
Physicians who frequently prescribe new drugs
have shown to be less cost-consciousness in
prescribing and to rely more on commercial
information sources (Jacoby, Smith & Eccles,
2003; Prosser & Walley, 2003). Adoption of new
drugs was also found to be associated with
physician gender, specialty, medical school, years
since graduation, practice location, practice size,
and proportion of elderly in the practice (Steffensen
et al., 1999; Tamblyn et al., 2003). On the other
hand, characteristics of the patient population of a
physician may also determine the need for prescrib-
ing new treatments (Bourgault, Rainville, & Suissa,
2001; Florentinus et al., 2005; Klungel, de Boer,
Paes, Seidell, & Bakker, 1998). To date, none of the
studies looking at determinants of drug adoption
considered the inﬂuence of all factors simulta-
neously and took possible differences in patient
populations into account.
The aim of this study was to identify determi-
nants for adoption of ARBs in routine prescribing
for hypertension by linking physician related
characteristics to their actual prescribing behaviour
while adjusting for patient characteristics.
Methods
Setting
The data reported in this study were collected
from 75 general practitioners (GPs) contributing to
the Integrated Primary Care Information (IPCI)
database in 2000–2003. The IPCI database is a
general practice research database which contains
information from computer-based patient records
of GPs in The Netherlands and is maintained by the
Erasmus Medical Center (van der Lei et al., 1993).
The ﬁrst practice was enrolled in the IPCI project in
1992 but a large proportion of practices started to
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GP records contain all relevant medical information
on individual patients, since patients are registered
to a single GP who has a gatekeeper role. To
maximize completeness of the data, GPs who
participate in the IPCI project are not allowed to
use paper-based records. The computer-based re-
cords contain information on patient demographics,
symptoms (free text), diagnosis (using the Interna-
tional classiﬁcation for primary care), referrals,
laboratory measurements, and drug prescriptions
(coded according to the anatomic therapeutic
chemical (ATC) classiﬁcation system)(WHO Colla-
boration Centre for Drug Statistics Methodology,
1999; World Organization of Family Doctors
(WONCA), 1998). The database complies with
European Union guidelines on the use of medical
data for medical research, and has been proven
valid using different reference methods for pharma-
co-epidemiological research (Greving et al., 2004;
Vlug et al., 1999). The Scientiﬁc and Ethical
Advisory Group of the IPCI project approved
the study.
Physician survey data
The GPs were asked to complete a questionnaire,
designed to be short and easy to complete in order
to optimize the response rate (Edwards et al., 2002).
Major domains of the questionnaire included
factors that may inﬂuence drug choice and the
adoption of new drugs (Denig et al., 1988; Rogers,
1995), i.e.: use of information sources, perceived
beneﬁts and risks of the drugs, the importance
attached to speciﬁc drug characteristics, profes-
sional network, and general physician characteris-
tics. The questionnaire items and format were pilot
tested for clarity and face validity among eight GPs
not related to the study population and revised
accordingly. A copy of the questionnaire can be
requested from the corresponding author.
GPs could ﬁrst indicate how often they used
various information sources in general (scientiﬁc
medical journals, practice guidelines, national drug
compendium, conferences/continuing education,
formularies, computerized prescribing support sys-
tem, pharmacotherapy counselling groups). Next,
they were asked how often they would use various
sources for information on the treatment of
hypertension on a scale from 1 (never) to 6 (always).
Included were four professional sources (i.e. scien-
tiﬁc medical journals, practice guidelines, nationaldrug compendium, conferences/continuing educa-
tion) and four commercial sources (i.e. pharmaceu-
tical representatives, journal advertisements, direct
mailings, sponsored meetings). Secondly, expectan-
cies and values regarding different antihypertensive
drug treatment aspects were measured. GPs were
asked to grade their expectations regarding efﬁcacy,
user-friendliness of the dosage schedule, side effects
and costs for each antihypertensive drug class on a
scale from 1 (low on efﬁcacy and user-friendliness;
high on side effects and costs) to 10 (high on efﬁcacy
and user-friendliness; low on side effects and costs).
This was used to calculate the perceived relative
expectancy of ARBs in comparison to the average
perceived expectancy of other antihypertensive drug
classes (i.e. diuretics, beta-blockers, calcium channel
blockers, angiotensin-converting enzyme inhibitors
(ACE-inhibitors)). GPs were also asked to rate the
importance of values attached to these aspects for
their choice of antihypertensive treatment on a scale
from 1 (not important) to 6 (important). Thirdly,
GPs could indicate how often they perceived the
inﬂuence of colleagues, hospital physicians and
patients to prescribe new antihypertensive drugs
on a scale from 1 (never) to 6 (always). Finally, GPs
provided data on demographic details including
age, gender, practice type (single-handed versus
partnership), practice location (urban versus rural),
practice size, workload, and work experience. GPs
were also asked about their membership in profes-
sional societies, their involvement in developing
guidelines, and their involvement in providing
pharmacotherapy education. Most Dutch GPs
participate in pharmacotherapy counselling groups
that meet at least four times a year to exchange
information and discuss pharmacotherapy. Not all
GPs, however, are personally involved in preparing
the content of these meetings. Additionally, GPs
were asked about their participation in trials with
antihypertensive drugs in the past ﬁve years.
The initial survey mailing was made in May 2003.
Telephone reminders and one follow-up mailing
were made to non-respondents to encourage a high
response rate.
Prescribing data for measuring adoption of ARBs
We were interested in the adoption of ARBs in
routine prescribing. Therefore, we looked at pre-
valent prescribing of ARBs to patients with
hypertension in the year 2000 as indicator for
adoption. This includes prescribing as initial or
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bination therapy. To assess prevalent prescribing,
we retrieved all prescriptions for antihypertensive
drugs (diuretics, beta-blockers, calcium channel
blockers, ACE-inhibitors, and ARBs) for patients
with hypertension in a 6-months period before our
index date (the ﬁrst Wednesday in October 2000).
This was roughly ﬁve years after the introduction of
the ﬁrst ARB in the Dutch market, and two years
before the results of large clinical trials on
cardiovascular endpoints on ARBs became avail-
able. Details on identiﬁcation of these patients have
been published elsewhere (Greving et al., 2004). In
brief, hypertension was identiﬁed from the medical
records by a search on ICPC-code (K85, K86, and
K87) and free text search on the diagnosis
hypertension followed by manual review. Data were
also collected on presence of comorbidities and
referrals to an internist or cardiologist.
Statistical analysis
Multivariable analyses were conducted to assess
the inﬂuence of physician level determinants on
prescribing ARBs rather than other antihyperten-
sive drugs. These analyses were preceded by
univariable analyses and data reduction procedures
to reduce the number of independent variables. We
assessed whether the use of professional and
commercial information sources on hypertension
treatment could be summated in two multi-item
scales with acceptable reliability (Cronbach’s alpha
40.70).
Determinants of adoption were studied by linking
physician related characteristics and views to their
actual prescribing behaviour of ARBs, taking into
account the possible effect of patient characteristics.
Because of the hierarchy in the data, i.e. clustering
of patients that receive care from the same GP, we
used multilevel logistic regression with patient
characteristics included at the ﬁrst level and GP
characteristics at the second level. All analyses were
performed with MlwiN software, version 1.2. The
multivariable multilevel models were built in two
steps. First, we developed a multivariable model for
all physician related variables, entering all variables
that were signiﬁcant at po0:10 level in the univari-
able analysis. All variables that remained signiﬁcant
at po0:05 level maintained into the ﬁnal model
(model 1). Second, we investigated the inﬂuence of
physician related characteristics after adjustment for
patient characteristics that could affect the prob-ability of receiving ARBs, such as age, gender,
presence of comorbidities, and referrals (model 2)
(Garcia del Pozo et al., 2004; Greving et al., 2004).
The inﬂuence of the variables on prescribing of




Seventy-two GPs completed the questionnaires
(response rate: 96%). Two GPs who worked in
partnership practices were excluded since they had
less than 20 registered hypertensive patients. The
ﬁnal study population comprised 70 GPs and 9470
patients with hypertension who had received anti-
hypertensive medication in the year 2000. These 70
GPs had a mean age of 49 years (SD 6), and were
mainly male (84%). The majority worked full-time
(65%), mostly in partnership practices and in urban
areas. The mean size of practice was 2435 patients
(SD 534). In this study, the percentage of males was
slightly higher, the percentage of GPs working in
urban areas was higher, and GPs were signiﬁcantly
older compared with the entire population of Dutch
GPs. There were no substantial differences in terms
of practice type and workload.
Of the 9470 patients treated for hypertension,
1093 patients were being prescribed ARBs (12%).
There was a considerable variation in the use of
ARBs between GPs (interquartile range, 6–15%).
Thirty-two percent of the patients were treated with
ACE-inhibitors, 21% received calcium channel
blockers, 41% beta-blockers, and 41% received
diuretics. On average, patients received 1.5 anti-
hypertensive drug prescriptions. Patients who were
treated with ARBs were more likely than other
hypertensive patients to be younger, to have asthma
or chronic obstructive pulmonary disease, and were
more likely to have been referred to an internist or
cardiologist (Table 1).
Multi-item scales
The four-item scale on use of commercial informa-
tion sources showed a high internal consistency
(Cronbach’s alpha ¼ 0.77), and a summated score
was therefore used for these commercial information
sources. No multi-item scale could be identiﬁed for
professional information sources because of lack of
internal consistency (Cronbach’s alpha o0.7).
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Table 1
Characteristics of prevalent users of angiotensin II receptor blockers versus other antihypertensive drugs classes in 2000
Characteristics Angiotensin II receptor blocker
users (n ¼ 1093)
Users of other antihypertensive
drug classes (n ¼ 8377)
P value
Mean7SD or number (%)
Age (years) 64.2712.6 66.0712.9 o0.001
Female 670 (61) 5189 (62) 0.691
Number of additional comorbidities 1.271.3 1.271.3 0.112
Angina pectoris 141 (13) 1108 (13) 0.812
Ankle oedema 119 (11) 977 (12) 0.482
Arrhythmia 136 (12) 879 (10) 0.054
Asthma/COPD 165 (15) 885 (11) o0.001
Diabetes 205 (19) 1472 (18) 0.333
Gout 62 (6) 493 (6) 0.837
Heart failure 60 (5) 539 (6) 0.261
Hypercholesterolemia 252 (23) 1764 (21) 0.135
Myocardial infarction 66 (6) 606 (7) 0.168
Proteinuria/renal insufﬁciency 29 (3) 243 (3) 0.701
Stroke 98 (9) 692 (8) 0.416
Referral to an internist 359 (33) 2288 (27) o0.001
Referral to a cardiologist 314 (29) 2031 (24) 0.002
COPD, chronic obstructive pulmonary disease.
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Multivariable analyses showed that adoption of
ARBs was associated with various determinants on
physician level (Table 2, model 1). Adjusting for
patient characteristics did not change the effects of
physician level variables (Table 2, model 2). ARB
prescribing was positively associated with frequent
use of commercial information sources (OR ¼ 2.0;
95% CI 1.5–2.6), but negatively associated with use
of a computerized prescribing decision support
system (OR ¼ 0.8; 95%CI 0.7–1.0). GPs involved
in providing pharmacotherapy education were less
inclined to prescribe ARBs (OR ¼ 0.7; 95%CI
0.5–0.9). Perceiving more beneﬁts of ARBs in
lowering blood pressure as compared to other
antihypertensive drug classes was associated with
higher adoption levels of ARBs. Finally, GPs who
worked in single-handed practices or in rural areas
were more likely to prescribe ARBs.
A number of factors appeared to be of little
inﬂuence. No signiﬁcant relation was observed
between use of scientiﬁc medical journals, continu-
ing education or other professional information
sources and adoption of ARBs. GPs differed in the
importance they assigned to speciﬁc drug character-
istics, such as the importance of choosing a drug
with high tolerability or low costs, but thesedifferences in values were not related to differences
in higher or lower adoption levels for ARBs. Also,
participation in trials was not a signiﬁcant factor.
Furthermore, ARB prescribing was not higher
among GPs who perceived more inﬂuence or
pressure of hospital physicians and patients to
prescribe newer antihypertensive drugs. Patients
who were referred to an internist or cardiologist,
however, were more likely to be treated with ARBs.
Discussion
Twelve percent of the hypertensive patients were
treated with ARBs in 2000, showing a clear
adoption of ARBs in routine prescribing. Market-
ing of pharmaceutical industries was the main
explanatory variable for variation in adoption
between GPs. The efforts put into implementing
clinical guidelines and practicing evidence-based
medicine have not altered this inﬂuence. Many of
the other potential determinants could not explain
the observed variation, indicating that the adoption
of ARBs was not driven by a preference for ARBs
based on a rational decision process nor by
professional or patient pressures. Further adjust-
ment for inﬂuences of specialist-initiated prescribing




Association between physician and patient characteristics and the physician’s choice to prescribe angiotensin II receptor blockers rather






Variables related to physicians (n ¼ 70)
Commercial information sources
Never/seldom 1 1 30 (43)
Average 1.23 (0.98–1.55) 1.25 (1.00–1.58) 31 (44)
Often/always 1.93 (1.48–2.52) 1.96 (1.51–2.56) 9 (13)
Use of a prescribing decision support system
No 1 1 36 (52)
Yes 0.80 (0.66–0.97) 0.80 (0.66–0.97) 33 (48)
Personal involvement in pharmacotherapy education
No 1 1 50 (72)
Yes 0.67 (0.51–0.88) 0.70 (0.53–0.92) 19 (28)
Perceived beneﬁts on blood pressure reduction (per mark
higher for ARBs vs. other drug classes)
1.17 (1.04–1.32) 1.19 (1.05–1.34) –
Practice type
Partnership 1 1 44 (63)
Single-handed 1.35 (1.10–1.65) 1.37 (1.12–1.69) 26 (37)
Practice location
Urban 1 1 36 (51)
Rural 1.67 (1.33–2.10) 1.76 (1.40–2.22) 34 (49)
Variables related to patients (n ¼ 9470)
Age (per year) 0.99 (0.98–0.99) —
Asthma/COPD
No 1 8420 (89)
Yes 1.51 (1.24–1.83) 1050 (11)
Myocardial Infarction
No 1 8798 (93)
Yes 0.74 (0.55–1.00) 672 (7)
Referral to a cardiologist
No 1 7125 (75)
Yes 1.41 (1.20–1.65) 2345 (25)
Referral to an internist
No 1 6823 (72)
Yes 1.31 (1.13–1.51) 2647 (28)
aMultilevel logistic regression model representing probabilities of prescribing ARBs as odds ratios, with 95% conﬁdence intervals.
Model 1: model with all signiﬁcant physician level variables (po0:05). Model 2: model with all signiﬁcant physician level variables adjusted
for patient characteristics. An odds ratio 41 means a higher adoption level of ARBs. CI, conﬁdence interval.
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regarding the adoption of ARBs, since ARB use for
hypertension ranged from less than 5% in the UK
to 20% in Norway in 2000 (Fretheim & Oxman,
2005). It was hypothesized that the low adoption
rate in the UK might be due to the efforts put into
implementing evidence-based guidelines, whereas
the high adoption rate in Norway might be the
result of seeding trials (Fretheim & Oxman, 2005).
Neither of these factors were the main driving forces
for differences between adoption of ARBs within
our country. We found that especially the use of
commercial information sources was related with
higher adoption levels of this new drug class.Although many doctors acknowledge that the
pharmaceutical industry tries to inﬂuence their
prescribing, only few recognise themselves as being
susceptible (Rutledge, Crookes, McKinstry, &
Maxwell, 2003). Physicians who prescribed more
ARBs did have a more positive perception of their
effectiveness in lowering blood pressure. However,
this is not an evidence-based judgment (Grobbee et
al., 2001). Although we cannot determine a causal
relationship, it is likely that promotional activities
of the pharmaceutical industry played a role in the
dissemination of these views. Pharmaceutical com-
panies in The Netherlands devoted substantial
resources to promote the advantages of ARBs in
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all, the amount of money spent on ARB promotion
in the year 2000 was 1.4 times higher than on all
other classes of antihypertensives together (IMS
Health, 2002b).
The ﬁnding that GPs using a computerized
prescribing decision support system have not
adopted ARBs at a high rate is promising, but
should be seen in the light that such systems were
only just becoming available on a large scale at the
time of our study. This implies that they could not
have played an important role in the adoption
process of ARBs in the period up to the year 2000. It
is therefore not clear whether the use of decision
support systems leads to better prescribing or
doctors who are better prescribers in the ﬁrst place
are more likely to use decision support systems.
Prescribing decision support systems can provide
evidence-based recommendations to clinicians dur-
ing the electronic prescribing process. There is some
evidence that this can lead to more rational and less
costly prescribing in primary care (McMullin et al.,
2004), but it has also become clear that these systems
are used in variable frequency by GPs (Brennink-
meijer, 2005; Rogers, Jain, & Hayes, 1999). It is
likely that especially GPs who already have a
positive attitude towards evidence-based and cost-
effective prescribing use these systems more fre-
quently. This kind of attitude may also explain why
personal involvement in providing pharmacotherapy
education is associated with prescribing less ARBs.
Cost-consciousness has been identiﬁed before as a
relevant factor for restrictive prescribing of new
drugs (Jacoby et al., 2003; Prosser & Walley, 2003).
Other studies showed that partnership practices
adopted new drugs faster than single-handed
practices, and suggested that continuous profes-
sional stimulation and other social factors might be
a reason for this accelerated adoption (Steffensen et
al., 1999; Williamson, 1975). We could not conﬁrm
this ﬁnding. On the contrary, adoption of new drugs
was faster among physicians working in single-
handed practices and in rural areas. This latter was
also observed in a previous study (Tamblyn et al.,
2003). Peer pressure was not found to be a driving
force for the adoption of ARBs. There was,
however, a clear effect of referrals to an internist
or cardiologist on ARB treatment. Most GPs
indicate that they usually continue prescriptions
initiated by a hospital physician.
As an indicator for adoption we used prevalent
prescribing of ARBs, since we aimed to identifydeterminants for the adoption of ARBs for routine
use in hypertension treatment. In previous studies,
we observed that the rapid increase in ARB
prescribing shortly after their introduction in the
market was not limited to speciﬁc patient groups or
initial prescribing (Greving et al., 2005; Greving
et al., 2004). Dybdahl et al. (2004) demonstrated
that most indicators of drug adoption correlate
well with each other, except for the indicator that
focuses on time until the ﬁrst prescription of a
new drug (Dybdahl et al., 2004). The latter is
not surprising since there is a clear difference
between the decision to prescribe a new drug for
the ﬁrst time ever and adopting a drug into routine
prescribing.
An important strength of our study is that we
were able to link GP, practice and patient char-
acteristics to actual prescribing patterns of ARBs.
The IPCI project gave us the advantage to achieve a
high response rate to our questionnaire survey
combined with the complete access to prescribing
data of their hypertensive patient population.
Consequently, there was a little chance of informa-
tion and selection bias. Although the percentage of
older, male GPs working in urban areas that
participated in our survey was slightly higher
compared to the entire population of Dutch GPs,
the trends in choice of antihypertensive treatment in
the period 1996–2000 correspond with general
trends in antihypertensive prescriptions in the
Netherlands (GIP, 2002; Greving et al., 2004; IMS
Health, 2002a). The database provided patient
speciﬁc information which enabled us to correct
for the possible effect of specialist-initiated pre-
scribing and patient characteristics. A limitation of
the study was that our survey was conducted in
2003, when the ﬁrst studies on hard endpoints of
ARBs had become available. This may have
changed the perception of GPs regarding this
aspect. We do not expect, however, that major
changes occurred regarding the use of information
sources, professional network, and general physi-
cian characteristics.
In summary, the adoption rate of a new drug
class is still determined more by the physicians’
reliance on promotional information than by their
use of professional information sources. Our ﬁnd-
ings underline the continuous need to implement
effective ways of dealing with the inﬂuence of the
pharmaceutical industry rather than relying on
promoting evidence-based medicine through tradi-
tional professional channels.
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